Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital

Similar documents
Clinical Laboratory. [None

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18

Clinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18

Test Name Results Units Bio. Ref. Interval

Autoantibodies panel ANA

Autoantibodies in the Idiopathic Inflammatory Myopathies

Tools to Aid in the Accurate Diagnosis of. Connective Tissue Disease

Test Name Results Units Bio. Ref. Interval

Disclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None

Is it Autoimmune or NOT! Presented to AONP! October 2015!

Autoimmune (AI) Disorders

Test Name Results Units Bio. Ref. Interval

NATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies

This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.

The Power of the ANA. April 2018 Emily Littlejohn, DO MPH

High Impact Rheumatology

Assays. New. New. Combinations. Possibilities. Patents: EP , AU

What will we discuss today?

Essential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT

MANAGING THE PATIENT WITH POSITIVE ANA

Rheumatology 101 A Pediatrician s Guide

Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

Insights into the DX of Pediatric SLE

University of Pretoria

Myositis and Your Lungs

Comparison of Performance of ELISA with Indirect Immunofluoresence for the Testing of Antinuclear Antibodies

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD

Autoantibodies giving rise to cytoplasmic IIF staining using HEp-2 cell substrate

Autoantibodies in Idiopathic Inflammatory Myopathies. Vidya Limaye Rheumatology Department Royal Adelaide Hospital

Rheumatologic Testing in Primary Care

Laboratory diagnosis of autoimmune diseases

Screening of Auto Antibodies using Indirect Immunofluorescence in Auto Immune Disease Patients

ANA Diagnostics Using Indirect Immunofluorescence

Rheumatology Primer: What Labs and When

Rheumatologic Lab Tests

Interpreting Rheumatologic Lab Tests

Comparison of indirect immunofluorescence and line immunoassay for autoantibody detection

ANA Screen ELISA Kit. Cat. No.:DEIA3138 Pkg.Size:96T. Intended use. General Description. Principle Of The Test. Reagents And Materials Provided

Atlas of Antinuclear Antibodies

9/13/2015. Nothing to disclose

Measurement of Antinuclear Antibodies: Assessment of Different Test Systems

Association of Immunofluorescence pattern of Antinuclear Antibody with Specific Autoantibodies in the Bangladeshi Population

Rhematologic serum testing is: Before request serologic tests, ANCA associated antigens c-anca: most commonly against the proteinase 3 (PR-3)

INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE

Conflict of Interest. Systemic Lupus Erythematosus and the Antiphospholipid Syndrome Bonnie L. Bermas, MD Brigham and Women s Hospital.

What are Autoantibodies and how do they work in Myositis?

Autoantibodies andprognosis. Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic

VASCULITIS PRODUCT HIGHLIGHTS

LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS

IdentRA test panel with eta. A clinically proven biomarker for earlier, accurate RA diagnosis and now, prognosis and monitoring

Detection of serum antinuclear antibodies in lymphoma patients

DISCUSSION BY: Dr M. R. Shakeebi, MD, Rheumatologist

Advances in Autoantibody Testing & Clinical Applications

ANA Diagnostics Using Indirect Immunofluorescence

International Journal of Pharma and Bio Sciences

Development of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.

What your autoantibodies tell us about your disease. Mark Gourley, MD

SLE-key Case Studies

Idiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya

Overview of Diagnostic Autoantibodies in Inflammatory Myopathy

IDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS. Franclo Henning Division of Neurology Tygerberg Hospital

Rheumatology Labs for the General Internist. Adam J Grunbaum DO FACOI FACR ACOI Annual Convention and Scientific Sessions 2018

For more information about how to cite these materials visit

Cutaneous manifestations and systemic correlation in patients with lupus erythematosus and its subsets: a study of 40 cases

Name and Intended Use

SLE and the Antiphospholipid Syndrome

Undifferentiated connective tissue diseases in 2004

Significance of antibody testing in idiopathic inflammatory myopathies

Alida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia

L. Nandini Moorthy, MD MS 2012

We also assessed the diagnostic significance of the SUBJECTS

Policy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

Autoimmune diagnostics. A comprehensive product line for the detection of autoantibodies

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

A Multiplex Autoantibody Panel for Early Detection of Autoimmune Disease Activity

*Pari Basharat ABSTRACT OVERVIEW OF IDIOPATHIC INFLAMMATORY MYOPATHIES

Marilina Tampoia, MD; Vincenzo Brescia, MD; Antonietta Fontana, MD; Antonietta Zucano, PhD; Luigi Francesco Morrone, MD; Nicola Pansini, MD

QUANTA Lite TM ANA ELISA

Acute Emergencies in Rheumatology

Scott Vogelgesang, MD Division of Rheumatology/Immunology University of Iowa

Mechanisms of Autontibodies

Inflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist

Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies

UPDATES ON PEDIATRIC SLE

Antibodies to nuclear antigens in polymyositis:

Significance of Anti-C1q Antibodies in Patients with Systemic Lupus Erythematosus as A Marker of Disease Activity and Lupus Nephritis

Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT

Lupus Erythematosus - Can Anti-SS-A Antibody Predict the Next Event?

Technical Article Series Scleroderma ANA and Antibody Testing

Determination and distribution of various antinuclear antibodies in systemic lupus erythematosus patients by using immunoblot testing

CTD-related Lung Disease

CSTAR CASE STUDIES: BLOCK F Type 3 Hypersensitivity Reaction

Immune tolerance, autoimmune diseases

Section: Medicine Effective Date: January 15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

Policy. Background

Review. Undifferentiated connective tissue diseases (UCTD): A review of the literature and a proposal for preliminary classification criteria

SCLERODERMA OVERLAP SYNDROME: A CASE REPORT Diwakar K. Singh 1, Nataraju H. V 2

Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016

Transcription:

Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital

Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases

Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases

Autoantibody : antibody against the individual's own proteins.

Autonuclear antibody (ANA) : autoantibodies directed against intracellular antigen Nuclear Chromatin associated antigen : DNA, Histone etc. Small Nuclear Ribonucleoproteins (snrnp) Other Ribonucleoproteins Nucleolar (Cytoplasmic)

Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases

Method for the Detection of Autoantibodies

IF-ANA : Gold standard for ANA testing American College of Rheumatology Slide collection

Hep-2 cells are grown on a microscope slide, fixed/permeabilized, and then incubated with a patient s diluted serum. After washing off unbound serum, the cells are incubated with fluorescently labeled goat anti-human IgG antibodies before viewing in an epifluorescence microscope. (b) ANA titer. Patient serum is diluted 1:40, and then serial twofold dilutions are performed and used to stain Hep-2 cells. In the example there is a weak fluorescent signal at 1:320 dilution and no staining at 1:640 (a 1:320 titer).

Homogeneous Peripheral Speckled Nucleolar

High sensitivity & specificity but technician dependent Previously used Ag substrate : rodent organ; liver, stomach In 1975, Human Epithelium cell line (HEp2 cells) was introduced to improve sensitivity.

American College of Rheumatology Slide collection

Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases

Chronic infectious diseases, such as mononucleosis, HCV, IE, TB, and HIV Lymphoproliferative diseases The presence of ANAs is rarely associated with malignancy, with the exception of dermatomyositis. Drugs : procainamide, hydralazine, chlorpromazine, quinidine, penicillamine, isoniazid, anti-tnf agents

Usefulness of testing for ANAs To help establish a diagnosis To exclude in patients with few or uncertain clinical findings To subclassify a patient To monitor disease activity Evaluated : pattern & titers

Anti-nuclear Antibodies (Patterns, Autoantigens, & Disease association) Homogenous Rim Speckled Nucleolar Histone ds-dna Sm U1-RNP Ro L a Scl-70 + High titer DIL SLE MCTD SS PSS

Anti-centromere : Can be seen during meiosis and mitotic phase Correlate with limited sclerosis, CREST syndrome

Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases

ANA diseases High prevalence of ANAs, often screened for by the fluorescent antinuclear antibody (FANA) test: SLE Systemic sclerosis (SSc) Mixed connective tissue disease (MCTD). The prevalence of ANAs in polymyositis (PM), dermatomyositis (DM), and Sjo gren s syndrome (SS) has been reported to be lower, but they are often grouped together.

Robbins Basic Pathology. 8 th edition

Common autoantibody in SLE Autoantibody Frequency IFA pattern Clinical correlation Anti-dsDNA 70-80% Homo, Rim Specific to SLE, correlate with disease activity (LN), bad prognostic serology Anti-ssDNA 90% Negative Non specific to SLE Anti-Histone 50-70% Homo Associated with drug induced Lupus, myositis, SSc, chronic infection (EBV) Anti-Sm 20-30% Speckle Specific to SLE Anti-U1 RNP 30-40% Speckle Good prognosis for SLE, MCTD like Anti-Ro 40% Speckle or Negative Neonatal LE, cutaneous lupus, sicca, lung involvement, Anti-La 10-15% Speckle Neonatal LE, late onset SLE, sicca, protect from anti-ro asso. nephritis Anti-Ribosomal P protein (anti-p) 10-20% Cytoplasm Neuropsychiatric LE, lupus hepatitis

Common autoantibody in Systemic sclerosis Autoantibody Frequency IFA pattern Clinical correlation Anti-Scl70 (Anti-topoisomearse1) Anti-Kinetochore (Anti-centromere) 22-40% Nucleolar Diffuse form, sclerodermal renal crisis, lung fibrosis 22-36% Centromeric Limited form, CREST syndrome, PHT Anti-RNAP III Nucleolar Diffuse form, sclerodermal renal crisis, Anti-U3RNP (Anti-fibrillalin) Nucleolar Diffuse form, PHT, internal organ involvement, myositis, lung involvement Anti-Th/T0 Nucleolar sclerodermal renal crisis, PHT Anti-PM-Scl Speckle Myositis-SSc overlap Anti-Ku Speckle Myositis, also found in SLE

Mixed Connective Tissue Disease (MCTD)

Common autoantibody in myositis Myositis-specific autoantibodies (MSAs) Myositis associated autoantibodies (MAAs) (myositis overlap autoantibodies) : Anti-snRNP, anti-pm-scl

Myositis-specific autoantibodies (MSAs) Autoantibody IFA pattern Clinical correlation Anti-Jo1 Cytoplasmic Anti-synthetase syndrome (Fever, arthritis, ILD, Raynaud s phenomenon, mechanic hand) Anti-Mi2 Speckle Dermatomyositis, good prognosis, good response to steroid Anti-CADM Amyopathic dermatomyositis Anti-TIF1γ (Anti-P155/140) Anti-SRP Anti-HMG-CoA Reductase Paraneoplastic syndrome Severe necrotizing myopathy, +/- cardiac involvement Statin induced necrotizing autoimmune myopathy (NAM)

Sjogren s syndrome Anti-Ro antibodies appear in approximately 40% to 95% of SS patients. Anti-La antibodies appear in as many as 87% of SS patients. Both antibodies correlated with extraglandular manifestations.

Red Flags for connective tissue disease Constitutional symptoms Arthralgia arthritis Photosensitive rash Urine abnormality Leukopenia Serositis Raynaud s phenomenon

Case 1 Female 25 years old Present with arthritis at small joints of hand with morning stiffness, rash at malar area, generalized edema. CBC WBC 3400, PMN 80%, L 15%, Hct 32%, Plt 120,000 Cr 0.5, Albumin 2.4 UA Protein 3+, RBC 3-5/HPF UPCI 4 gm/day

Case 1.1 ANA 1:320 Homogeneous pattern 1:640 Speckle pattern

ANA : negative Case 1.2

ANA negative SLE Protein losing condition Inappropriate substrate Prozone phenomenon Anti-Ro, Anti-ssDNA Complement deficiency True ANA negative SLE (less than 5%)

Case 2 Female 65 years old Present with constitutional symptoms, weight loss 6 kg/2 months, mild arthritis both hands, no rash. Mild splenomegaly, LN not palpable. CBC WBC 22,000, PMN 25%, L 65%, Hct 22%, Plt 90,000 PBS : microspherocyte, polychromasia, Lymphocyte predominate, platelet decrease DCT positive

Case 2 ANA 1:160 Speckle pattern Anti-dsDNA, Anti-Sm : negative

Case 3 Female 30 years old Present with prolonged fever 2 months with weight loss 10 kg, arthritis both hands, LCV both legs, Raynaud s phenomenon + Fine crepitation both lungs

Case 3 ANA 1:160 Speckle pattern Anti-dsDNA, Anti-Sm : negative Anti-HIV positive, Anti-HCV positive

Clinical features Idiopathic SLE Drug-induced Lupus Age / Sex Young / Female Older / Male (Children) Onset Insidious Abrupt Severity Severe Mild Systemic symptoms Common Common Musculoskeletal symptoms Common Common Polyserositis Common Common Multi-organ involvement Common Unusual Classical skin lesions Common Unusual CNS, renal involvement Common Rare Complements Decreased Normal ANA Anti Sm, Anti-DNA Anti-(H2A-H2B)-DNA Therapeutic trail No response Improvement